Race/Ethnicity Affects Access and Survival Differences After Neoadjuvant or Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients-Reference-Cited by-同舟云学术

Race/Ethnicity Affects Access and Survival Differences After Neoadjuvant or Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients

Published:2024-08-19 Issue: Volume: Page:
ISSN:2197-3792
Container-title:Journal of Racial and Ethnic Health Disparities
language:en
Short-container-title:J. Racial and Ethnic Health Disparities

Author:

de Angelis Mario^ORCID,Jannello Letizia Maria Ippolita,Siech Carolin,Di Bello Francesco,Peñaranda Natali Rodriguez,Goyal Jordan A.,Tian Zhe,Longo Nicola,de Cobelli Ottavio,Chun Felix K. H.,Puliatti Stefano,Saad Fred,Shariat Shahrokh F.,Gandaglia Giorgio,Moschini Marco,Montorsi Francesco,Briganti Alberto,Karakiewicz Pierre I.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40615-024-02131-9.pdf

Reference26 articles.

1. Flaig TW, Spiess PE, Abern M. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Cancer Netw. 2022 Aug;20(8):866–78.

2. Witjes JA, Bruins HM, Cathomas R. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104.

3. Grossman HB, Natale RB, Tangen CM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.

4. Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76–86.

5. The R Project for Statistical Computing. https://www.r-project.org. Accessed 2022.